Kenneth et al. have indicated that pioglitazone could halt the proliferation of PTEN‐deficient lung cancer cells and enhance their sensitivity to EGFR tyrosine kinase inhibitor (To et al., 2018); shedding light on the ability of pioglitazone to induce cell death in cancer cells with mutant PTEN. This evidence concerns the gene PTEN and cancer.